Sanofi Other Non-Current Liabilities 2010-2024 | SNY

Sanofi other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Sanofi other non-current liabilities for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Sanofi other non-current liabilities for 2023 were $10.763B, a 13.59% increase from 2022.
  • Sanofi other non-current liabilities for 2022 were $9.476B, a 14.22% decline from 2021.
  • Sanofi other non-current liabilities for 2021 were $11.047B, a 0.15% increase from 2020.
Sanofi Annual Other Non-Current Liabilities
(Millions of US $)
2023 $10,763
2022 $9,476
2021 $11,047
2020 $11,030
2019 $11,008
2018 $11,309
2017 $11,506
2016 $11,301
2015 $11,426
2014 $14,238
2013 $12,777
2012 $15,930
2011 $16,271
2010 $12,899
2009 $11,591
Sanofi Quarterly Other Non-Current Liabilities
(Millions of US $)
2024-09-30
2024-06-30 $11,517
2024-03-31
2023-12-31 $10,763
2023-09-30
2023-06-30 $10,445
2023-03-31
2022-12-31 $9,476
2022-09-30
2022-06-30 $9,527
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $11,506
2017-09-30
2017-06-30 $10,671
2017-03-31
2016-12-31 $11,301
2016-09-30
2016-06-30 $12,337
2016-03-31
2015-09-30
2015-06-30 $11,436
2014-06-30 $13,773
2013-06-30 $14,250
2012-06-30 $16,223
2012-03-31
2011-12-31 $16,271
2011-09-30
2011-06-30 $15,963
2011-03-31
2010-12-31 $12,899
2010-09-30
2010-06-30 $11,860
2010-03-31
2009-12-31 $11,591
2009-09-30
2009-06-30 $11,793
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $130.241B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Innoviva (INVA) United States $1.263B 10.51